Pfizer Lilly: Different Bets on Pharma M&A Explained
Eli Lilly posts a blockbuster start to 2026 as Pfizer works to rebuild after the COVID era, highlighting pfizer lilly...
An overview of which total market fund performed best in 2024, with notes on expense, tracking error, and performance drivers.
28,518 articlesEli Lilly posts a blockbuster start to 2026 as Pfizer works to rebuild after the COVID era, highlighting pfizer lilly...
XRP stalls after a rejection at the 100-day moving average, with price around $1.37 as bulls weigh the next move. Key...
In a shock move, TapTools announced it will wind down operations within 14 days after a wave of leadership departures...
Congressional leaders broker a bicameral agreement that bans a federal digital currency before 2030 while reviving ho...
Meta Platforms has shown business momentum even as its stock traded lower. This guide weighs the case to buy, sell, o...
Lofty and Showami roll out a direct integration that enables on-demand showings within the Lofty CRM, aiming to speed...
Choosing between two healthcare giants comes down to balance: steady income or longer-term growth. This guide dives i...
In a Friday decision, the Tenth Circuit refused to hear Custodia Bank's final appeal, ending a five-year battle for d...
Three of the world’s largest drinks companies are signaling divergent paths in 2026: Diageo reset its balance sheet, ...
Unisys (UIS) 2026 earnings could hinge on services growth, margin discipline, and backlog strength. This guide breaks...
Biotech earnings season shines a spotlight on Delcath Systems. This guide breaks down the 2026 earnings outlook, key ...
Oklo stock fell further as traders digested quarterly results and a new regulatory filing. This article breaks down w...